Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia

Blood. 2012 Jul 19;120(3):697-8. doi: 10.1182/blood-2012-04-421016.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dasatinib
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Pharmacogenetics / methods
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Receptors, KIR / genetics*
  • Receptors, KIR / metabolism
  • Thiazoles / therapeutic use*

Substances

  • KIR2DS1 protein, human
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Receptors, KIR
  • Thiazoles
  • Dasatinib